Source: Financial Supervisory Service Dart System / 2025-02-25
Disclosure Type: Changes of 30% or More (15% or More for Large-Scale Corporations) in Revenue or Profit/Loss Structure
💡 3-Second Summary
Celltrion’s FY2024 consolidated revenue increased by 63.45% year-on-year to approximately KRW 3.56T driven by global prescription growth, while its operating profit declined by 24.48% to KRW 492B due to the cost of sales increase from consolidated inventory valuation and amortization following the merger.
📊 1. [Key Disclosure Content & Major Figures Summary]
- Consolidated Income Statement Changes:
- Revenue: KRW 3,557,303,554,000 (approx. KRW 3.56T) / Up 63.45% compared to previous FY (Change: +KRW 1,380,872,023,000)
- Operating Profit: KRW 492,015,535,000 (approx. KRW 492B) / Down 24.48% compared to previous FY (Change: -KRW 159,465,887,000)
- Income Before Income Taxes: KRW 576,116,811,000 (approx. KRW 576.1B) / Down 14.15% compared to previous FY (Change: -KRW 94,978,974,000)
- Net Profit: KRW 418,883,310,000 (approx. KRW 418.9B) / Down 22.39% compared to previous FY (Change: -KRW 120,823,195,000)
- Consolidated Balance Sheet Summary:
- Total Assets: KRW 21,055,222,438,000 (approx. KRW 21.06T)
- Total Liabilities: KRW 3,475,160,069,000 (approx. KRW 3.48T)
- Total Equity: KRW 17,580,062,368,000 (approx. KRW 17.58T)
- Registered Capital: KRW 220,508,291,000 (approx. KRW 220.5B)
- Additional Disclosure:
- Separate Revenue: KRW 3,709,213,743,000 (approx. KRW 3.71T)
- Total Equity Excluding Non-Controlling Interest: KRW 17,439,141,579,000 (approx. KRW 17.44T)
- Primary Drivers of Financial Variations:
- Revenue: Driven by the expansion of global prescriptions for existing products and the growth of subsequent new offerings.
- Operating Profit: Affected by an increase in the cost of sales ratio from selling higher-valued inventory acquired via the merger with Celltrion Healthcare, amortization of intangible assets such as marketing rights arising from the merger, and increased selling, general, and administrative (SG&A) expenses due to the expansion of international sales subsidiaries to boost export volumes.
- Net Profit: Affected by the decrease in operating profit.
📈 2. [Expert Perspective: What This Means for Investors]
- Growth in Revenue Coupled with Contraction in Profits: Celltrion delivered top-line expansion with annual consolidated revenue of KRW 3.56T, rising 63.45% year-on-year. However, operating profit (approx. KRW 492B) and net profit (approx. KRW 418.9B) fell by 24.48% and 22.39% respectively, showing contrasting directions between top-line expansion and bottom-line earnings metrics.
- Impact of Merger Consolidation and Expenses: The decline in operating profit is directly attributed to the sale of higher-valued inventories acquired during the merger with Celltrion Healthcare, alongside the recognition of amortization costs for intangible marketing rights. Operational SG&A costs also rose as the company expanded its foreign sales subsidiaries to support increased export volumes.
- Pre-Audit Preliminary Figures: The disclosed financial data is based on preliminary figures prepared internally by the company. As noted in the disclosure, these metrics have not been audited by the external auditor and may be subject to adjustment, meaning investors should look to the subsequent official audit report filing to verify these numbers.
📝 Editor’s Comment (by K-STOCK Editor)
Celltrion has disclosed major changes in its consolidated financial and earnings structure for the fiscal year. While the company achieved top-line expansion exceeding KRW 3.5 trillion due to global market prescription growth, its profitability indicators faced compression from merger-related inventory valuations and administrative expansion costs.
The immediate check point for investors moving forward is the official submission of the finalized annual audit report. Because the current disclosure is compiled based on internal preliminary calculations, investors must compare these preliminary metrics with the verified financials in the upcoming audited filings to check for any modifications.
Additionally, as the filing outlines specific factors affecting operating margins—such as high-value inventory realization and intangible asset amortization following the merger with Celltrion Healthcare—investors are advised to monitor future periodic financial reports to check whether these operational cost pressures stabilize in upcoming quarters.
📢 Disclaimer & Sources
Source: This content was structured and newly generated based on official disclosure data submitted to the Financial Supervisory Service (DART) of South Korea.
Investment Risk Notice: This information is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest solely with the investor.
Inquiries: For compliance queries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
